January 19, 2017Open Access

T‐cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer

JLJianfeng LiuHarbin Medical University SMSi‐Rui MaGansu University of Traditional Chinese Medicine LMLiang MaoCalifornia Institute of Technology

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

cells and decreasing MDSCs. Our findings demonstrate TIM3 expression in patients with HNSCC and suggest anti-TIM3 immunotherapy as a novel therapeutic approach for effective treatment of HNSCC.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Liu et al. (Thu,) studied this question.

synapsesocial.com/papers/6a01e9f1897643a80dcb1b0a https://doi.org/https://doi.org/10.1002/1878-0261.12029

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck2007 · 280 citations
2Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients2011 · 52 citations
3Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles2007 · 2,168 citations
4Cancer statistics, 20142014 · 11,570 citations
5The molecular biology of head and neck cancer2010 · 2,557 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo